08:00 | Registration |
|
Session 1 |
| Session Chair: Eugene Zhukovsky, Chief Scientific Officer, Biomunex Pharmaceuticals, France |
| |
09:30 | Cross-Neutralising Single Domain Antibodies to Influenza – Preparing for the Next Pandemic
Simon Hufton, Section Head Molecular Immunology, National Institute for Biological Standard and Control (NIBSC), United Kingdom
Single domain antibodies (nanobodies) and their applications to influenza vaccine potency testing and immunotherapy will be discussed.
|
10:00 | Monoclonal Antibody Therapy for the Management of Severe Asthma
Suzanne Cohen, , MedImmune, United Kingdom
Severe asthma involves a number of variants with different underlying pathologies. Genome Wide Association Studies have consistently implicated IL-33 and its receptor ST2 in asthma. IL-33 itself has intriguing biochemistry that has implications for antibody discovery. |
10:30 | Coffee & Networking in Exhibition Hall |
11:00 | Antibody-Mediated Neonatal Protection Against Respiratory Syncytial Virus
Shamir Jacobino, Researcher, University Medical Center Utrecht, Netherlands
RSV is a leading cause of lower respiratory tract infections in young infants. We provide the first evidence that virus-specific antibodies in the lungs of neonates originating from amniotic fluid can protect in the critical first weeks of newborns. |
11:30 | Living Droplets – Microfluidic Antibody and Vaccine Discovery at Very High Throughput
Christoph Merten, Principal Investigator, European Molecular Biology Laboratory, Germany
This presentation will discuss droplet based microfluidics for the direct screening of millions of primary murine (from spleen and bone marrow) and human (from blood) plasma cells. It will also discuss assays for antibody binding, inhibition of enzymatic drug targets, effect on target cells. Compatability with difficult targets such as GPCRs and the screening of vaccine candidates.
|
12:00 |  Technology Spotlight:
Novel Assay Formats using NanoLuc® Luciferase Technology for Homogeneous Immunoassay, Immunogenicity and Receptor-ligand Blockade
Craig Malcolm, Strategic Collaborations Manager, Promega UK Ltd
This talk will describe recently developed assays using NanoLuc® luciferase technology applied to PK/immunogenicity studies and a no-wash, homogeneous immunoassay format. In addition, data will be presented on cell-based BRET assays for quantifying antibody biologic mediated blocking of receptor-ligand interactions.
|
12:15 |  Technology Spotlight:
Cyto-Mine® – An Enabling Platform for Biologic Drug Discovery and Development
Frank Gesellchen, Senior Scientist, Sphere Fluidics
Picodroplet technology can be used to find rare and valuable variants within heterogeneous cell populations. We are developing the Cyto-Mine® Single Cell Analysis and Monoclonality Assurance System which leverages this cutting-edge approach for the discovery of novel biotherapeutics.
|
12:20 | Lunch & Networking in Exhibition Hall |
13:00 | Poster Viewing Session |
13:15 |  Free Workshop
Obtaining Reliable Binding Kinetics for Biomolecular Interactions Workshop
|
|
Session 2 |
| Session Chair: Christoph Merten, Principal Investigator, European Molecular Biology Laboratory, Germany |
| |
14:15 | Enabling Cancer Immunotherapy, From Target to Phenotype
Andrew Green, Senior Drug Discovery Specialist, Discoverx, United Kingdom
This presentation will highligh innovative microtiter plate based assays to interrogate immune checkpoint receptors and introduce KILR™ |
14:45 | Cancelled due to ill Health - Identification of Novel Neo-Epitopes on Antibodies Generated through Chemical Degradation: Relevance for Potency and Immunogenicity
Christian Schoneich, Professor, University of Kansas, United States of America
This presentation will give an overview over novel degradation reactions and products of proteins with relevance for the generation of stable protein formulations and immunogenicity. |
15:15 | BiXAb(R) is a Versatile Modular Platform for the Development of Bispecific Antibodies
Eugene Zhukovsky, Chief Scientific Officer, Biomunex Pharmaceuticals, France
Plug-and Play BiXAb® platform enables generically applicable bispecific antibody design from any pair of monospecific mAbs. These bispecific antibodies possess excellent manufacturability, superior drug-like properties, and potent activity in vivo models. We will discuss a case study of the BiXAb® for the treatment of EGFR+/HER2+ solid tumors. |
15:45 | Coffee & Networking in Exhibition Hall |
16:15 | Efficient Mining of the Natural Antibody Repertoire – Next Generation Antibody Discovery
Daniel Lightwood, Director, UCB Pharma, United Kingdom
An overview of UCB’s unique antibody discovery platform and how we are integrating droplet microfluidics to increase efficiency. A case study will also be presented. |
16:45 | Discovering and Engineering Antibodies by High-throughput Repertoire Sequencing
Sai Reddy, Assistant Professor, ETH Zurich, Switzerland
The ability obtain a greater molecular understanding of antibody responses may enable new approaches in engineering and discovery of mAbs. Recent advances in high-throughput immunoglobulin (antibody) repertoire sequencing (Ig-seq) are enabling highly quantitative analysis of antibody responses. |
17:15 | High Precision Protein Folding and Aggregation Analytics by NanoDSF
Claire Hatty, Application Specialist, NanoTemper, United Kingdom
NanoDSF is an advanced Differential Scanning Fluorimetry (DSF) method for measuring ultra-high resolution protein stability using intrinsic tryptophan fluorescence, while simultaneously measuring aggregation in the sample. Applications include protein engineering, membrane protein research, antibody formulation development and quality control. |
17:45 | Drinks Reception in Exhibition Hall |
20:00 | Conference Dinner in Hinxton Hall |
22:00 | End of Day 1 |
